Phylloceuticals

Phylloceuticals is a private U.S. biotechnology company developing a plant-based platform for the rapid discovery, development, and manufacture of therapeutic proteins and other biologics. The company positions its PhAAST platform, short for Pharmaceuticals as a Service Technology, as a lower-cost, faster alternative to conventional mammalian-cell bioprocessing for biosimilars, novel therapeutics, vaccines, and animal health products. Its public materials emphasize plant-made pharmaceuticals, rapid candidate screening, and decentralized manufacturing models intended to expand access to medicines in underserved regions. Phylloceuticals appears to be at an early commercial and preclinical stage, with announced technical progress including production of a PD-1 inhibitor monoclonal antibody and establishment of a pilot facility in Rapid City, South Dakota. The company is not publicly traded and appears to operate primarily as a platform and strategic development partner rather than as a single-asset therapeutics developer.